RetinaVue™ Network

Breakthrough technology makes diabetic retinopathy screening SIMPLE and AFFORDABLE for primary care.

See how the RetinaVue Network can help identify and reduce one of the leading causes of preventable blindness.

RV100_3_percentages

414 million people are living with diabetes. That number will grow to 642 million by 2040.

More than 80% of patients living with diabetes will develop diabetic retinopathy. 

On average, less than half of all diabetics receive potentially vision-saving diabetic retinal exams (DREs). 


Introducing the Welch Allyn RetinaVue Network

retinavue-aquired

Welch Allyn
RetinaVue™ 100 Imager

The world's most advanced, handheld
fundus camera captures high-quality
images in minutes.

FDA Listing #D258266
retinavue-network-software

Welch Allyn
RetinaVue™ Network Software

Secure, HIPAA-compliant server to
transfer encrypted images and review
patient results.

FDA Listing #D150615
retinavue-PC-Dr-Chaum

Welch Allyn 
RetinaVue™ P.C.

Diagnostic interpretation services via 
a network of board-certified, fellowship-
trained retina specialists.

 
2X_RV100_graphic

RetinaVue Network can increase patient compliance rates for diabetic retinal assessment up to 90% in 12 months, helping to preserve vision and increase quality metrics


Improve Quality Metrics and Revenue 

5_STARS_RetinaVue

Annual retinal examinations are included in the NCQA® HEDIS® ratings program, the Medicare Advantage STAR quality rating program, and Medicare quality ratings program.

 

“In the category of Medicare diabetes retinal screenings, [RetinaVue] helped our client, Summit Medical Group, move from a one-star quality rating to a four-star rating by one of its major insurance providers within one year.”

–Jack Kam, executive leader and chief science & innovation officer for Summit Strategic Solutions

RetinaVue_Edward_Chaum

It is like adding a retina specialist to your team.

“In addition to identifying, classifying and documenting all levels of diabetic retinopathy from very mild to vision threatening, we have also been able to diagnose a surprising assortment of important systemic diseases based on RetinaVue fundus images—including papilledema, hypertension, macular degeneration (AMD), cancer and stroke.”

EDWARD CHAUM, M.D., PH.D.
Chief Medical Officer, RetinaVue P.C.

Request a demo today!

*
*
*
*
*
*
*
*
*